Introduction
The intensity of the pharmacologic or toxic effect of a drug is considered to be related to the concentration of the drug at the receptor sites, which are usually located in the tissue cells.
In practice, the plasma drug level is generally employed for monitoring the course of therapy, 0.100 to 0.272 M in 0.1 N HCl (Table I ). In addition, the solubility of nifedipine was decreased by about 10% with increment of the ionic strength from 0.110 to 0.222 M in the phosphate buffer (pH 7) ( Table I ). The release rates, however, were less influenced by these differences in ionic strength. Similar results were reported by Baggesen and Bechgaard17): the release rates of propoxyphene hydrochloride from pellets were not much influenced by ionic strength between 0.097 and 0.133 M. These results indicate that the pH-independent release granules prepared in the present study might be relatively impervious to factors such as pH, peristaltic movement, bile, or ionic strength of the GI fluid in the alimentary tract. The mean plasma nifedipine levels of the sustained-release granules were higher over the 2-12 h period than those in the case of the soft gelatin capsule. The pharmacokinetic parameters for the two formulations are not directly comparable since the dose of nifedipine administered as granules was double the dose in the capsule. However, dose proportionality studies of nifedipine established linear kinetics.5"'6,18) Thus, after correcting for the dose by multiplying Cmax and AUC0-12h by 2 for the capsule, these parameters were analyzed statistically (Table II) . The peak plasma level for the granules was significantly lower (p < 0.05) than that for the capsule (Table II) . The extent of bioavailability of the granules was about 75% of the capsule, which was similar to that found in rabbits previously. The tmax value for the granules was larger than that for the capsule (Fig. 2) , but there was no statistically significant difference (at p > 0.05) in AUC0 -12, or tmax values between the two formulations. When the pharmacokinetic parameters were compared for the two formulations for unequal variances, the Cmax and A UC0 _12 h values after administration for the granules were significantly smaller (p < 0.05) than those of the capsule (Table II) . This smaller inter-subject variability may be attributed to the following factors. (1) The granular formulation which is a type of multiple-units dosage form19) would be dispersed quickly in the stomach and scattered through the small intestine, where they would be distributed widely.20) Thus, inter-subject variability caused by differences in the transit time are minimized with such formulations. (2) The sustained-release granules prepared in the present study would be less influenced by factors such as pH and ionic strength in the GI fluid, peristaltic movement, or bile, based on the results obtained from the release studies in vitro. The hypotensive effect of nifedipine in hypertensive patients was related to the plasma leve121) and the minimum nifedipine level required for the effect was 10 15 ng/m1.51,c,22) Thus the patients should receive capsules every 6 h (total: 40 mg/d) based on the results shown in Fig. 5 . However, the granular formulation would be expected to be effective even if the patients receive it every 12 h (total: 40 mg/d). The plasma levels at 4, 6, 9 and 12 h after administration of the granules were significantly higher (p < 0.05) than those after the capsule (Fig. 2) , though the dose of nifedipine administered as granules was double the dose in the capsule. A plasma level of about 13 ng/ml at 12 h post-dosing was detected after administration of the granules. If two nifedipine soft gelatin capsules (equal to the dose of the sustained-release granules) are administered to the subjects, high peak plasma levels might produce severe side effects. The slower release of nifedipine from the granules may minimize the side effects, which are a result of high plasma levels.23) Furthermore, it is easy to adjust the dose of the pH-independent release granules to correspond to the severity of the disease, but difficult to do so with a commercial sustained-release tablet5a-c) or controlled-release capsule which contains rapid release and slow release granules.5d)
In conclusion, a higher plasma level was detected over the 2-12 h period, and no great inter-subject variability was noted after oral administration of the nifedipine sustained-release granules prepared in the present study. Twice-daily dosing should be sufficient for therapeutic effectiveness. Thus, this formulation is expected to improve the compliance of patients. 
